Fri, January 6, 2012
Thu, January 5, 2012
Wed, January 4, 2012
Tue, January 3, 2012
Mon, January 2, 2012
Sat, December 31, 2011
Fri, December 30, 2011
Thu, December 29, 2011
Wed, December 28, 2011
Tue, December 27, 2011
Mon, December 26, 2011
Fri, December 23, 2011
Thu, December 22, 2011
Wed, December 21, 2011

Alexion to Host Conference Call This Morning to Discuss Companyas Proposed Acquisition of Enobia Pharma Corp.


//health-fitness.news-articles.net/content/2011/ .. -proposed-acquisition-of-enobia-pharma-corp.html
Published in Health and Fitness on Thursday, December 29th 2011 at 3:20 GMT by Market Wire   Print publication without navigation


CHESHIRE, Conn.--([ ])--As previously announced, Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) will conduct a conference call at 9:00AM Eastern Time today, December 29, to discuss the Companyas proposed acquisition of Enobia Pharma Corp. To access the live call, please dial 1-888-297-0356 (U.S.) or 1-719-325-2109 (international). The conference passcode number is 5470489. Telephone replay will be available for a limited period following the call, beginning at 12:00PM Eastern Time. The replay number is 888-203-1112 (USA) or 719-457-0820 (International), confirmation code 5470489. The audio webcast can be accessed at [ www.alexionpharma.com ].

About Alexion

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Alexion is the global leader in complement inhibition, and has developed and markets Soliris (eculizumab) as a treatment for patients with PNH and aHUS, two debilitating, ultra-rare and life-threatening disorders caused by chronic uncontrolled complement activation. Soliris is currently approved in more than 35 countries for the treatment of PNH, and in the United States and the European Union for the treatment of aHUS. Alexion is evaluating other potential indications for Soliris and is pursuing development of other innovative biotechnology product candidates in early stages of development. This press release and further information about Alexion Pharmaceuticals, Inc. can be found at: [ www.alexionpharma.com ].


Publication Contributing Sources